Esperion Therapeutics Inc
(NAS:ESPR)
$
2.12
0.12 (6%)
Market Cap: 415.99 Mil
Enterprise Value: 472.28 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 53/100 
Esperion Therapeutics Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019 / 08:50PM GMT
Release Date Price:
$40
(+3.31%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
So welcome. I'm Marty Auster. I'm the lead SMID cap biotech analyst at Crédit Suisse, joined now by Esperion Therapeutics. We have CEO, Tim Mayleben; and the Chief Commercial Officer, Mark Glickman. And I wish we could do this more than once a year, Tim.
Timothy M. Mayleben
Esperion Therapeutics, Inc. - President, CEO & Director
So do all of our assembled panelists.
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Exactly. Thanks, everyone, for joining us, and thanks for coming. So let's talk about Esperion. I'm sure you'd like to kind of just maybe provide just a little overview of kind of where you're at? Obviously, you've had a pretty busy year since we saw you last November.
Timothy M. Mayleben;Martin Douglas Auster<
Esperion Therapeutics, Inc. - President, CEO & Director
Yes.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers